Exosomal profile change during Durvalumab treatment

Exploratory study on exosomal profile change during Durvalumab treatment - Exosomal profile change during Durvalumab treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042280

Enrollment

Registered

2020-10-29

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients: Stage III NSCLC patients treated with CRT and subsequent durvalumab treatment. All patients provided written informed consent

Exclusion criteria

Exclusion criteria: Exclude NSCLC patients with other types of cancer.

Design outcomes

Primary

Measure	Time frame
Time course changes of proteome profiles of circulating exosomes isolated from the serum of NSCLC patients treated with durvalumab.	—

Countries

Japan

Contacts

Public ContactFujita Yu

The Jikei University School of Medicine Department of Translational Research for Exosomes

yuugot@jikei.ac.jp03-3433-1111

Outcome results